Scientists uncover 3 key brain pathways linked to lasting depression relief — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mount Sinai researchers identified three brain white matter pathways—the cingulum bundle, forceps minor, and medial uncinate fasciculus/ventral amygdalofugal pathways—whose stimulation was consistently linked to lasting improvement in patients receiving subcallosal cingulate deep brain stimulation (SCC DBS) for treatment-resistant depression.
- The study, published October 1 in the American Journal of Psychiatry, analyzed the largest multi-cohort patient group assembled to date, pooling data from the BROADEN trial and a University of Toronto cohort originally treated by SCC DBS pioneer Helen Mayberg.
- Patients who failed to respond after two years showed a consistent pattern of insufficient stimulation engagement with the left cingulum bundle, suggesting that millimeter-level differences in electrode placement can determine whether critical connections are actually activated.
- Helen Mayberg, Brian Kopell, and Ki Sueng Choi said the findings support 'connectome-based targeting'—using individualized brain connectivity maps rather than anatomical landmarks to guide electrode placement—a strategy already shaping Abbott's ongoing randomized TRANSCEND clinical trial.
- The researchers cautioned that reaching the three pathways is a necessary but likely insufficient condition for response, and noted limitations including the lack of individual diffusion MRI scans for every participant, forcing much of the analysis to rely on generalized connectivity maps.
- Several co-authors, including Mayberg and Kopell, disclosed paid consulting roles with Abbott Laboratories; Mayberg is also a named co-inventor of the SCC DBS method licensed to Abbott and holds a pending co-inventor patent on the connectome-based targeting technique.
Why it matters: For the small subset of patients whose severe depression has not responded to conventional treatment, getting electrode placement within millimeters of the right white matter pathways could determine whether deep brain stimulation delivers lasting relief or two years of nonresponse—a precision question that now anchors Abbott's TRANSCEND randomized trial and could redefine how DBS for depression is surgically planned.
Ask SkimNews
